Memorandum - POC #8

To: UNC Health Attending Physicians, Faculty Practice Physicians, Housestaff, Clinical Nurse Coordinators, Department Heads and Supervisors

From: Nichole Korpi-Steiner, PhD, Director, UNCMC Point of Care Testing
Steven Cotten, PhD, Director, UNCH Children's Raleigh Lab and POCT
Jason Merker, MD, PhD, Acting Medical Director, McLendon Clinical Labs

Date: May 26, 2026

Subject: Point of Care HbA1c testing using reagent lot # 0926075

Effective May 26, 2026, point of care HbA1c testing using Siemens DCA Vantage reagent lot # 0926075 should implement an intercept offset (0.2%).

Re-evaluation of DCA reagent lot # 0926075 demonstrated a negative bias (falsely low) in measured values compared to lab testing; accordingly, an intercept offset of 0.2% is needed to better align POC HbA1c results with lab testing. **This intercept offset is specific to this reagent lot # 0926075.**

Recommendations for CLIA Lab Director(s):

- If DCA Vantage reagent lot # 0926075 was received, program the DCA Vantage analyzer(s) with intercept offset of 0.2% for patient testing.
- Report any patient safety incident(s) via online SAFE reporting system.

If indicated, submit official complaint regarding DCA Vantage performance to Siemens Healthineers by calling Technical Support line at 1-877-229-3711, prompt 14, then prompt 1.

If you have any question related to this change, please contact POC office at 984-974-1416, or Dr. Korpi-Steiner at 984-974-1498 or Nichole.korpi-steiner@unchealth.unc.edu